LABNET - RAPIDLY DEPLOYABLE AUTONOMOUS LABORATORY

LABNET - 可快速部署的自主实验室

• 批准号: 10505108
• 负责人: EDDIE MCABEE
• 金额: $ 32.49万
• 依托单位: CFD RESEARCH CORPORATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2022-06-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10505108
• 关键词: Antibodies; Artificial Intelligence; Automation; Biological Assay; Biotechnology; COVID-19 pandemic; Cloud Computing; Computer software; Data Collection; Data Storage and Retrieval; Enzyme-Linked Immunosorbent Assay; Goals; Laboratories; Laboratory Research; Liquid substance; Machine Learning; Modeling; Nonprofit Organizations; Pharmacologic Substance; Phase; Rapid screening; Research; Social Distance; System; Time; Universities; assay development; base; cloud based; data exchange; design; drug discovery; experimental study; innovation; instrument; instrumentation; molecular diagnostics; prototype; tool

Laboratory automation is a key innovation that can help overcome the social distancing requirements due to the 2020 COVID-19 pandemic. Although, automation instruments have been used for decades in high throughput settings, they have not transitioned to routine laboratory research. Moreover, current laboratory automation lacks machine learning and artificial intelligence that can help guide design of experiments based on real-time analytics. The overall goal of the proposed project is to develop and commercialize a scalable software and hardware system, LABNET, which will integrate artificial intelligence (AI) tools, autonomous and modular laboratory instruments for data transmission and storage, and cloud computing for multi-scale and machine-learning (MS-ML) modeling and analytics for laboratory research. Phase I will focus on design and demonstration of the system to perform automated ELISA assays which will be guided by AI suite of tools for rapid screening of antibodies using a commercial off-the-shelf liquid handling system. Phase II will focus on integration of additional instrumentation, biological assays and high throughput instrumentation. The developed product will be commercialized to pharmaceutical, biotech companies, research labs, universities and non-profit organizations involved in assay development, molecular diagnostics and drug discovery.

实验室自动化是一项关键创新，可以帮助克服2020年新冠肺炎疫情带来的社交距离要求。虽然自动化仪器已经在高通量环境中使用了几十年，但它们还没有过渡到常规的实验室研究。此外，目前的实验室自动化缺乏机器学习和人工智能，这些机器学习和人工智能可以帮助指导基于实时分析的实验设计。拟议项目的总体目标是开发可扩展的软件和硬件系统LabNet并将其商业化，该系统将整合人工智能(AI)工具、用于数据传输和存储的自主和模块化实验室仪器，以及用于实验室研究的多尺度和机器学习(MS-ML)建模和分析的云计算。第一阶段将专注于设计和演示系统，以执行自动化的ELISA分析，该系统将由人工智能工具套件指导，使用商业现成的液体处理系统快速筛选抗体。第二阶段将侧重于整合更多的仪器、生物检测和高通量仪器。开发的产品将向制药、生物技术公司、研究实验室、大学和参与分析开发、分子诊断和药物发现的非营利性组织商业化。